Senesco Technologies, Inc
Senesco is running a Phase 1/2 study in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients with a novel gene regulatory approach. The ability of eukaryotic translation initiation factor 5A (eIF5A) to modulate critical pathways involved in cancer and inflammatory diseases is being investigated.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Senesco Technologies, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Senesco Technologies, Inc
2 distinct titles indexed · top 2 shown.
- 1president
- 1welder
Sign up to unlock all 3 contacts at Senesco Technologies, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Senesco Technologies, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.